Compare Quest Diagnostics Inc (DGX) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Alphabet Inc Class A — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Alphabet Inc Class A trades at $370.32 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 191.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | GOOGL | |
|---|---|---|
Market Cap | $22.80B | $4.37T |
Sector | Health | Media |
52-Week High | $216.02 | $402.62 |
52-Week Low | $166.42 | $182.00 |
Enterprise Value | $28.82B | $4.34T |
Dividend Yield | 1.67% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Alphabet (GOOGL) trades at $370.92, up 5.22% over the past day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 estimate. Revenue grew to $402.84 billion in 2025, up from $350.0 billion in 2024, while net income increased to $132.17 billion. Analyst sentiment remains overwhelmingly positive, with 85% recommending a buy and a consensus price target of $431.78.
The outlook for GOOGL is positive, driven by robust revenue growth, expanding profit margins, and leadership in AI and cloud infrastructure. Key risks include regulatory scrutiny, competitive pressures in digital advertising, and market volatility. The stock presents a compelling opportunity for growth investors, supported by strong fundamentals and bullish analyst coverage, though investors should be mindful of execution and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
